• Publications
  • Influence
The biology of VEGF and its receptors
Vascular endothelial growth factor (VEGF) is a key regulator of physiological angiogenesis during embryogenesis, skeletal growth and reproductive functions. VEGF has also been implicated inExpand
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
The addition of bevacizumab to fluorouracil-based combination chemotherapy results in statistically significant and clinically meaningful improvement in survival among patients with metastatic colorectal cancer. Expand
Vascular endothelial growth factor: basic science and clinical progress.
  • N. Ferrara
  • Biology, Medicine
  • Endocrine reviews
  • 1 August 2004
Vascular endothelial growth factor (VEGF) is an endothelial cell-specific mitogen in vitro and an angiogenic inducer in a variety of in vivo models and is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration. Expand
The biology of vascular endothelial growth factor.
The establishment of a vascular supply is required for organ development and differentiation as well as for tissue repair and reproductive functions in the adult1. Neovascularization (angiogenesis)Expand
VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
It is shown that VEGF-mediated capillary invasion is an essential signal that regulates growth plate morphogenesis and triggers cartilage remodeling and VEGf is anessential coordinator of chondrocyte death, chondROclast function, extracellular matrix remodeling, angiogenesis and bone formation in the growth plate. Expand
Vascular endothelial growth factor is a secreted angiogenic mitogen.
DNA sequencing suggests the existence of several molecular species of VEGF, a heparin-binding growth factor specific for vascular endothelial cells that is able to induce angiogenesis in vivo. Expand
Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR.
Purified PIGF isoforms had little or no direct mitogenic or permeability-enhancing activity, but were able to significantly potentiate the action of low concentrations of VEGF in vitro and, more strikingly, in vivo. Expand
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
The unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12 was reported, and angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Expand
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumour angiogenesis and that blockingAngiogenesis is an effective strategy to treat human cancer. Expand
HIF-1alpha is essential for myeloid cell-mediated inflammation.
It is found that activation of HIF-1alpha is essential for myeloid cell infiltration and activation in vivo through a mechanism independent of VEGF, and its direct regulation of survival and function in the inflammatory microenvironment is demonstrated. Expand